Author Interviews, Cancer Research, Genetic Research / 18.04.2019
RNA Genetic Testing Improves Analysis of Hereditary Cancer Genes
MedicalResearch.com Interview with:
Rachid Karam, PhD
Director, Ambry Translational Genomics Lab
Ambry Genetics
MedicalResearch.com: What is the background for this study?
Response: DNA genetic testing (DGT) for hereditary cancer genes is now a well accepted clinical practice; however, the interpretation of DNA variation remains a challenge to laboratories and medical providers.
RNA genetic testing (RGT) as a supplement to DGT is a means to clarify the clinical actionability of variants in hereditary cancer genes, improving our ability to accurately apply known strategies for cancer risk reduction.
Rachid Karam, PhD
Director, Ambry Translational Genomics Lab
Ambry Genetics
MedicalResearch.com: What is the background for this study?
Response: DNA genetic testing (DGT) for hereditary cancer genes is now a well accepted clinical practice; however, the interpretation of DNA variation remains a challenge to laboratories and medical providers.
RNA genetic testing (RGT) as a supplement to DGT is a means to clarify the clinical actionability of variants in hereditary cancer genes, improving our ability to accurately apply known strategies for cancer risk reduction.